Study of PTC299 in Relapsed/Refractory Acute Leukemias | Aplastic Anemia & MDS International Foundation Identifier:



PTC Therapeutics

Contact Info

Mary Frances Harmon
(866) 282-5873


Start: October 2018
End: November 2020

Official Title

Study of PTC299 in Relapsed/Refractory Acute Leukemias


This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.

Study of PTC299 in Relapsed/Refractory Acute Leukemias

Clinical Trial: NCT03761069


If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.

Phase 1
Age Group: 
18 years and older
Accepts Healthy Volunteers: 
Inclusion Criteria: 

Participant must have relapsed/refractory AML and exhausted standard available therapies known to provide clinical benefit.

Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (≤) 2

Women of childbearing potential must be practicing a highly-effective method of birth control for up to 50 days after the last dose of study drug.

A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control for up to 50 days after the last dose of study drug.

Participants must be willing to participate to the study, have the ability to understand and adhere to study visit schedule and other protocol procedures, and be able and willing to sign a written informed consent form.

Exclusion Criteria: 

Medical history:

Women who are or plan to become pregnant, or who are currently breastfeeding.

Persistence of any clinically relevant (Common Terminology Criteria for Adverse Events [CTCAE] Grade 2 or above) toxicities from previous therapy.

Active alcohol or drug abuse.

Previous drug-induced liver injury.

Cardiac assessments:

Uncontrolled congestive heart failure, unstable angina pectoris.

History or current evidence of a myocardial infarction during the last 6 months.

QTc prolongation greater than (>) 500 milliseconds (msec) (Fridericia formula).

Congenitally long QT syndrome or has received any marketed or experimental compound in the last 4 weeks or 5 half-lives (whichever is shorter) prior to entering the study with possible or known effects of QT prolongation. (If equivalent medication is not available, QTc will be closely monitored.)

Laboratory assessments:

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) greater than or equal to (≥) upper limit of normal (ULN).

Serum bilirubin ≥ ULN (except those known to have Gilbert's syndrome).

Creatinine clearance ≤ 45 milliliters per minute (mL/min).

Any laboratory abnormality, which in the opinion of the investigator, places the subject at an unacceptably high risk for toxicities.

Gastrointestinal (GI) assessments:

Liver malignancy (including metastases) or chronic liver disease.

History of GI surgery or procedures or conditions that might interfere with the absorption or swallowing of the study drug.


Known hypersensitivity to study drug or its excipients.


Any sign of active uncontrolled infections; any severe chronic disease potentially interfering with the protocol, including human immunodeficiency virus (HIV) infection, or active hepatitis B or C or those with a positive screen for hepatitis A Immunoglobulin M (IgM).

Any other malignancies within the past 2 years other than basal cell skin cancer or carcinoma in situ of the cervix.

Participant concomitantly receiving any other investigational agents.

Systemic chemotherapy within 2 weeks or investigational therapy within 5 half-lives prior to first dose of study drug, unless there is evidence of rapidly progressive disease; persistent chronic clinically significant toxicities from prior chemotherapy must not be >Grade 1. For monoclonal antibodies, the washout from prior therapy will be 4 weeks. Use of hydroxyurea (Hydrea) is permitted up to 24 hours prior to start of study drug for control of proliferative disease. Participant with central nervous system (CNS) involvement.

Participant is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.

Participant is receiving CYP2B6 substrates such as bupropion and methadone.

Participant is receiving strong CYP3A4 inducers such as carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, and St. John's wort (hypericin) or drugs that are exclusively substrates of CYP3A4.

Participant is receiving moderate or strong CYP3A4 inhibitors.

Find Out More:


AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored content is highlighted only to give additional information about the trial. All trials are listed on Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a clinical trial, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.